Litcius/Paper detail

Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation

Kirk M. Chan‐Tack, Patrick R. Harrington, Timothy J. Bensman, Suyoung Choi, Eric Donaldson, Julian J. O’Rear, David McMillan, L. Peyton Myers, Mark Seaton, Hanan Ghantous, Yu Cao, Thamban Valappil, Debra Birnkrant, Kimberly Struble

2021Antiviral Research79 citationsDOI

Topics & Concepts

Food and drug administrationSmallpoxGovernment (linguistics)MedicineCountermeasureDrug approvalAdministration (probate law)BiodefenseDrug developmentRegulatory affairsRegulatory scienceBusinessPolitical scienceEnvironmental healthDrugPublic administrationVirologyPharmacologyEngineeringLawAerospace engineeringLinguisticsVaccinationPhilosophyPathologyPoxvirus research and outbreaksViral gastroenteritis research and epidemiologyVirus-based gene therapy research
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation | Litcius